Lytix Biopharma AS (DE:6BG) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Lytix Biopharma AS successfully raised NOK 100 million in a private placement and an additional NOK 11.3 million through a retail offering on the PrimaryBid platform, attracting strong interest from both new and existing investors. The capital will be used to accelerate the development of its lead drug candidate, LTX-315, towards commercialization and advance the next-generation molecule LTX-401 into clinical trials. The company plans to conduct a subsequent repair offering to mitigate dilution effects for current shareholders.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.
